The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters

被引:41
|
作者
Winkler, Ulrich H. [1 ]
Sudik, Roland [2 ]
机构
[1] Clin Wetzlar Braunfels, Dept Obstet & Gynaecol, D-33578 Wetzlar, Germany
[2] Klinikum Neubrandenhurg, Dept Obstet & Gynecol, D-17036 Neubrandenburg, Germany
关键词
Chlormadinone acetate; Ethinyl estradiol; Desogestrel; Oral contraceptive; VENOUS THROMBOEMBOLIC DISEASE; RISK; LIPOPROTEINS; MORTALITY; ETHINYLESTRADIOL; 3RD-GENERATION; BELARA(R); ESTROGEN; ACNE;
D O I
10.1016/j.contraception.2008.08.011
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background: This study was conducted to compare the effects of two monophasic oral contraceptives (OCs) containing ethinyl estradiol (EE) 30 mcg+either chlormadinone acetate (CMA) 2 mg (Belara (R)) or 0.15 mg desogestrel (Marvelon (R)) on lipid, hormone and other relevant metabolic parameters. Study design: Markers of lipid and carbohydrate metabolism, and reproductive hormone levels, were measured in 45 Subjects randomly assigned to 6 months of treatment with one of the two OCs. The cortisol response to adrenocorticotrophic hormone (ACTH) stimulation was also evaluated. Results: In both treatment groups, triglycerides, high-density lipoprotein cholesterol (HDL-C), apolipoprotein (Apo) Al and Apo All levels increased; low-density lipoprotein cholesterol (LDL-C) and the LDL-C/HDL-C ratio decreased; and total cholesterol and lipoprotein(a) were unchanged during treatment. Effects on HDL-C, Apo Al, LDL-C and the LDL-C/HDL-C ratio were more evident in the EE 30 mcg+CMA 2 mg group. Follicle-stimulating hormone, luteinizing hormone and androgen levels decreased and sex hormone-binding globulin levels increased in both groups. Both OCs increased basal cortisol levels and cortisol response to ACTH. Oral contraceptive did not have a clinically significant impact on carbohydrate metabolism. Conclusions: Both low-dose monophasic OCs had comparable effects on lipid, hormone and metabolic parameters during six cycles of treatment in healthy female subjects. There was some evidence of a beneficial effect on atherogenic cardiovascular risk markers, which was slightly more pronounced with EE 30 mcg+CMA 2 mg. (C) 2009 Published by Elsevier Inc.
引用
收藏
页码:15 / 23
页数:9
相关论文
共 27 条
  • [1] A comparative study of the hemostatic effects of two monophasic oral contraceptives containing 30 μg ethinylestradiol and either 2 mg chlormadinone acetate or 150 μg desogestrel
    Winkler, U. H.
    Daume, E.
    Sudik, R.
    Oberhoff, C.
    Bier, U.
    Hallmann, C.
    Andreas, J. O.
    Schindler, A. E.
    EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 1999, 4 (03) : 145 - 154
  • [2] HEMOSTATIC AND METABOLIC EFFECTS OF LOWERING THE ETHINYL-ESTRADIOL DOSE FROM 30 MCG TO 20 MCG IN ORAL-CONTRACEPTIVES CONTAINING DESOGESTREL
    BASDEVANT, A
    CONARD, J
    PELISSIER, C
    GUYENE, TT
    LAPOUSTERLE, C
    MAYER, M
    GUYGRAND, B
    DEGRELLE, H
    CONTRACEPTION, 1993, 48 (03) : 193 - 204
  • [3] A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 μg ethinyl estradiol and a reference containing desogestrel and 30 μg ethinyl estradiol
    Kluft, C
    Endrikat, J
    Mulder, SM
    Gerlinger, C
    Heithecker, R
    CONTRACEPTION, 2006, 73 (04) : 336 - 343
  • [4] Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on lipid metabolism during 1 year of conventional or extended-cycle use
    Wiegratz, Inka
    Stahlberg, Skadi
    Manthey, Torsten
    Saenger, Nicole
    Mittmann, Katrin
    Palombo-Kinne, Ernesta
    Mellinger, Uwe
    Lange, Evelyn
    Kuhl, Herbert
    CONTRACEPTION, 2010, 81 (01) : 57 - 61
  • [5] Effects of two combined oral contraceptives containing ethinyl estradiol 30 μg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure
    Yildizhan, Recep
    Yildizhan, Begum
    Adali, Ertan
    Yoruk, Pinar
    Birol, Fatih
    Suer, Necdet
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2009, 280 (02) : 255 - 261
  • [6] MULTICENTER TRIAL OF 2 MONOPHASIC ORAL-CONTRACEPTIVES CONTAINING 30 MCG ETHINYLESTRADIOL AND EITHER DESOGESTREL OR GESTODENE IN THAI WOMEN
    KOETSAWANG, S
    CHAROENVISAL, C
    BANHARNSUPAWAT, L
    SINGHAKOVIN, S
    KAEWSUK, O
    PUNNAHITANONT, S
    CONTRACEPTION, 1995, 51 (04) : 225 - 229
  • [7] Effects of two combined oral contraceptives containing ethinyl estradiol 30 μg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure
    Recep Yildizhan
    Begum Yildizhan
    Ertan Adali
    Pinar Yoruk
    Fatih Birol
    Necdet Suer
    Archives of Gynecology and Obstetrics, 2009, 280 : 255 - 261
  • [8] Investigation of the hemostatic effect of a transdermal patch containing 0.55 mg ethinyl estradiol and 2.1 mg gestodene compared with a monophasic oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel: An open-label, randomized, crossover study
    Junge W.
    Heger-Mahn D.
    Trummer D.
    Merz M.
    Drugs in R&D, 2013, 13 (3) : 223 - 233
  • [9] A combined oral contraceptive containing 30 mcg ethinyl estradiol and 3.0 mg drospirenone does not impair endothelium-dependent vasodilation
    Meendering, Jessica R.
    Torgrimson, Britta N.
    Miller, Nicole P.
    Kaplan, Paul F.
    Minson, Christopher T.
    CONTRACEPTION, 2010, 82 (04) : 366 - 372
  • [10] Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on thyroid hormones and androgen parameters:: conventional vs. extended-cycle use
    Saenger, Nicole
    Stahlberg, Skadi
    Manthey, Torsten
    Mittmann, Katrin
    Mellinger, Uwe
    Lange, Evelyn
    Kuhl, Herbert
    Wiegratz, Inka
    CONTRACEPTION, 2008, 77 (06) : 420 - 425